Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups Kumar Jeetendra | August 1, 2020 HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated …
Translational exploration preparing program causes understudies to more readily comprehend patients’ issues Kumar Jeetendra | September 27, 2020 Translational research aims to speed research breakthroughs into the practice. And yet, training for basic scientists and clinicians too often remains siloed, resulting in divergent cultures and a lack of chance for cross-disciplinary collaboration. The South Carolina Clinical & Translational Research (SCTR) Institute’s TL1 application, a translational research training program for doctoral students in the …
Researchers grow first plant-based gel to help organoid development for biomedical applications Kumar Jeetendra | November 26, 2020 Monash University researchers have created the world’s first bioactive plant-based nanocellulose hydrogel to support organoid growth and help significantly reduce the costs of research into cancer and COVID-19. This discovery by researchers in BioPRIA (Bioresource Processing Institute of Australia), Monash University’s Department of Chemical Engineering and the Monash Biomedicine Discovery Institute will develop organoids cheaper, …
Hematoxylin compounds can specifically kill CALR mutant cancer cells Kumar Jeetendra | December 11, 2020 Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR). Researchers of the research team of Robert Kralovics, Adjunct Principal Investigator in the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and team leader at the …
Hematoxylin compounds can specifically kill CALR freak disease cells Kumar Jeetendra | December 20, 2020 Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR). Scientists of the research group of Robert Kralovics, Adjunct Principal Investigator in the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and team leader at the …
Hydrogel injection could help fix harm to the heart muscle after heart attack Kumar Jeetendra | February 19, 2021 Researchers at CÚRAM, the SFI Research Centre for Medical Devices based at NUI Galway, and BIOFORGE Lab, at the University of Valladolid in Spain, have developed an injectable hydrogel which might help repair and prevent additional damage to the heart muscle following a heart attack occasion. The results of their research have only been published …
CN Bio presents the PhysioMimix™ OOC Multi-Organ Microphysiological System Kumar Jeetendra | March 17, 2021 CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS. The next-generation system unites CN Bio’s in vitro 3D liver model, whose phenotype and functions mimic that in vivo, with a range of other organs to …
Small molecule drug can weaken the triggers of neuroinflammation, preclinical review shows Kumar Jeetendra | September 24, 2021 Neuroinflammation may cause worse outcomes in cases of stroke, injuries to the brain or injury, and can increase the severity of neurodegenerative diseases such as ALS, Parkinson’s, or Alzheimer’s. This suggests that reducing neuroinflammation might be an exciting new method to treat neurological disorders and neuropathic pain caused by neuroinflammation. In a preclinical study , …
